等级
pharmaceutical primary standard
API类
olsalazine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
InChI
1S/C14H10N2O6.2Na/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22;;/h1-6,15,17H,(H,19,20)(H,21,22);;/q;2*+1/p-2/b16-8-;;
InChI key
QQWFSVYVHLECFP-XBPUGJBTSA-L
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Olsalazine sodium for performance test EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Lynn W Maines et al.
Inflammopharmacology, 18(2), 73-85 (2010-02-13)
Activation of sphingosine kinase (SK) is a key response to many inflammatory processes. The present studies test the hypothesis that an orally available SK inhibitor, ABC294640, would be effective in rodent models of Crohn's disease. Trinitrobenzene sulfonic acid (TNBS) was
T-M-H Nguyen et al.
International journal of clinical pharmacology and therapeutics, 48(4), 275-281 (2010-04-01)
Aminosalicylates are widely used with azathioprine in the treatment of IBD. The association results in an increase in 6-TGN levels in adults with IBD with a difference in the occurrence of myelotoxic effects. Scarce data are available in pediatric population.
When less is not more but at least equivalent.
Stephen Holland
Inflammatory bowel diseases, 10(6), 890-891 (2005-01-01)
Danial E Baker et al.
Reviews in gastroenterological disorders, 4(2), 86-91 (2004-06-10)
5-aminosalicylic acid agents are effective in the treatment of ulcerative colitis. Balsalazide, mesalamine, and olsalazine are alternative formulations to sulfasalazine for the delivery of 5-aminosalicylic acid. The newer compounds might be better tolerated than sulfasalazine in some patients, as long
David T Rubin et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 4(11), 1346-1350 (2006-10-25)
Aminosalicylates have been suggested as chemopreventive agents for colorectal cancer (CRC) in ulcerative colitis (UC). We studied the effect of aminosalicylate use on dysplasia and CRC risk in chronic UC. UC patients with dysplasia or CRC were matched with controls
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门